Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Denver news in your inbox

Catch up on the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Des Moines news in your inbox

Catch up on the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Minneapolis-St. Paul news in your inbox

Catch up on the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tampa Bay news in your inbox

Catch up on the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Charlotte news in your inbox

Catch up on the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Rebecca Zisser / Axios

Once disparate fields of science are intersecting in unprecedented ways — physicists are flocking to solve biology's complex problems, geologists and astronomers mind meld over the search for alien life, and ecologists and economists collaborate to try to figure out how we compete and cooperate. Axios Science, which launches today, will cover these intersections where ideas are colliding and the questions they answer.

Biology + computer science: Axios talked with Vijay Pande, a physicist/biologist who is now a general partner at Silicon Valley investment firm Andreessen Horwitz where he oversees their portfolio of companies that apply computation to medicine.

Why it matters: "Genomics and machine learning are converging in ways that are bound to change medicine and disrupt health care. Investors are pouring in money and scientists are asking — and answering — questions they couldn't before. Here's what Pande had to say about artificial intelligence making a mark on medicine and how understanding life as simply a way to convey information, can turn medicine from "a hardware problem to a software problem."

What biology and computation have in common: "As human beings we might not like to think of ourselves this way but we, like other mammals, like other vertebrates, like other multicellular organisms, like other organisms are largely vehicles for replicating DNA. In the wholeness of our lives with our families and children, we've accomplished our job once we've gotten our children out and they are ready to continue to replicate the DNA all the way down. From that perspective the goal of life is all about information. It is often described as a metaphor but it is very deep. That's what partially is so appealing about genomics: it turns this problem that looks like what in the computer world we would call a hardware problem into a software problem."

Moore's Law for biology: "Much like the iPhone being cheap enabled all of these apps, I think we are going to see a ton of apps built on genomic measurements. It's not just going to be the genome you were born with — that you need to get measured probably only once. It will be the genome and signals from your body about tumor cells and cancer that you want to get [measured] twice a year to make sure you haven't developed cancer. There will also be all the epigenetic changes, where your body is constantly having its DNA methylated and acetylated. All of these changes are happening in real time and being able to understand that is going to be huge. This represents so much poorly understood biology that now finally because this can be done at scale at low cost, we're going to have a huge amount of information."

The app he would build on the human platform: "That is like asking me in the candy store which piece of candy do I want first. The obvious places to start are disease: the big killers will be heart disease and cancer. That reflects our investment priorities. Freenome is working to put out a test that is relatively inexpensive that can tell through genomics whether you have early stage cancer. Another portfolio company of ours, Cardiogram, put out study results where they used the Apple Watch to, with very high accuracy, detect atrial fibrillation."

"Another thing to think about that has been weighing on my mind a great deal is rethinking health care more generally. There has been a lot of excitement about health extension and longevity extension where people could live healthier not through their 80s but through 100, 110, 120. What would it take to do that?"

Machine learning meets biology: "We've seen the early victories but there is still work to do to be able to take all of the atoms in your body and all the information associated with it and turn it into a format that machines can learn."

"In many cases, we don't have a ton of data. Especially in the area of drug design. You have a lot less data than you would when you are trying to train an algorithm to identify images. How can you look at a drug and tell whether it is successful? We think about drugs as locks and keys - the drug is the key, the protein is the lock. Often you compare keys to each other and you can tell whether it will open the same lock. The idea is that one shot learning can learn that so we can line up two models and tell you if this [drug] is successful, I think this one will also be successful."

How AI will change science itself: "Where machine learning and biology are perfectly suited for each other is that machine learning is great at complexity, nuance, detail and absorbing tons of data and biology has tons of data, complexity, nuance and detail."

"Machine learning and the human being — the biologist and the doctor — will be able to do things together that no human being could ever do alone. Our ability then to dive into this complexity and wrap our head around it is overwhelming. I think in the next 20 years there will a rapid pace in new biological insights, things we just couldn't learn before. I've got my popcorn ready. I am super excited to watch the show."

Go deeper

Updated 3 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Eniola Odetunde/Axios

  1. Health: Most vulnerable Americans aren't getting enough vaccine information — Fauci says Trump administration's lack of facts on COVID "very likely" cost lives.
  2. Politics: Biden unveils "wartime" COVID strategyBiden's COVID-19 bubble.
  3. Vaccine: Florida requiring proof of residency to get vaccine — CDC extends interval between vaccine doses for exceptional cases.
  4. World: Hong Kong to put tens of thousands on lockdown as cases surge.
  5. Sports: 2021 Tokyo Olympics hang in the balance.
  6. 🎧 Podcast: Carbon Health's CEO on unsticking the vaccine bottleneck.

Trump impeachment trial to start week of Feb. 8, Schumer says

Senate Majority Leader Chuck Schumer. Photo: The Washington Post via Getty

The Senate will begin former President Trump's impeachment trial the week of Feb. 8, Majority Leader Chuck Schumer announced Friday on the Senate floor.

The state of play: Schumer announced the schedule after reaching an agreement with Republicans. The House will transmit the article of impeachment against the former president late Monday.

4 hours ago - Health

CDC extends interval between COVID vaccine doses for exceptional cases

Photo: Joseph Prezioso/AFP via Getty

Patients can space out the two doses of the coronavirus vaccine by up to six weeks if it’s "not feasible" to follow the shorter recommended window, according to updated guidance from the Centers for Disease and Control and Prevention.

Driving the news: With the prospect of vaccine shortages and a low likelihood that supply will expand before April, the latest changes could provide a path to vaccinate more Americans — a top priority for President Biden.